Medicus Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:N460 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
15 Nov 24	Buy€385,224	James Quinlan	Individual	98,760	€3.90
15 Nov 24	Buy€385,224	Edward Brennan	Individual	98,760	€3.90
28 Jun 24	Buy€1,425	James Quinlan	Individual	622.5	€2.29
28 Jun 24	Buy€2,324	Francis Lavelle	Individual	622.5	€3.73
28 Jun 24	Buy€2,138	Erica Monaco	Individual	934	€2.29
28 Jun 24	Buy€356	Carolyn Bonner	Individual	155.5	€2.29
28 Jun 24	Buy€4,277	RBx Capital LP	Company	1,868	€2.29

Insider Trading Volume

Insider Buying: N460 insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of N460?
Owner Type	Number of Shares	Ownership Percentage
VC/PE Firms	3,707,504	31.6%
General Public	3,912,021	33.4%
Individual Insiders	4,107,255	35%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.2%.

Top Shareholders

Top 13 shareholders own 66.64% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
24.9%	Velocity Fund Management	2,914,330	€7.8m	0%	no data
17.1%	Ajay Raju	2,000,000	€5.3m	0%	no data
6.76%	RBx Capital LP	793,174	€2.1m	0.25%	100.0%
6.73%	John Hathaway	789,202	€2.1m	0%	no data
3.81%	Louis Falo	446,763	€1.2m	0%	no data
3.49%	Kenneth Melani	409,411	€1.1m	0%	no data
1.74%	James Quinlan	203,908	€545.0k	93.9%	no data
1.38%	Edward Brennan	161,260	€431.0k	158%	no data
0.33%	Erica Monaco	38,434	€102.7k	0%	no data
0.22%	Francis Lavelle	25,622	€68.5k	0%	no data
0.16%	Carolyn Bonner	18,905	€50.5k	-0.01%	no data
0.11%	Robert Ciaruffoli	12,500	€33.4k	0%	no data
0.011%	William Ashton	1,250	€3.3k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 09:07
End of Day Share Price	2025/01/02 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medicus Pharma Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kumaraguru Raja	Brookline Capital Markets
Jason McCarthy	Maxim Group
Steven Ralston	Zacks Small-Cap Research